Format

Send to

Choose Destination
Nat Chem Biol. 2014 Feb;10(2):96-8. doi: 10.1038/nchembio.1405. Epub 2013 Dec 1.

Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA.

Author information

1
Ecole Polytechnique Fédérale de Lausanne, Global Health Institute, Lausanne, Switzerland.
2
Discovery Sciences, Innovative Medicines, AstraZeneca, Cheshire, UK.
3
Swiss Federal Institute of Technology (ETH) Zürich, Institute of Pharmaceutical Sciences, Zürich, Switzerland.

Abstract

Pyridomycin, a natural product with potent antituberculosis activity, inhibits a major drug target, the InhA enoyl reductase. Here, we unveil the co-crystal structure and unique ability of pyridomycin to block both the NADH cofactor- and lipid substrate-binding pockets of InhA. This is to our knowledge a first-of-a-kind binding mode that discloses a new means of InhA inhibition. Proof-of-principle studies show how structure-assisted drug design can improve the activity of new pyridomycin derivatives.

PMID:
24292073
DOI:
10.1038/nchembio.1405
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center